Motorola Solutions Inc vs Nuvalent Inc — how do they compare? Motorola Solutions Inc trades at $405.33 (market cap $68.13B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Motorola Solutions Inc is far larger — about 6.9× Nuvalent Inc's market cap, and Motorola Solutions Inc pays a 1.18% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MSI | NUVL | |
|---|---|---|
Market Cap | $68.13B | $9.81B |
Sector | Technology | Technology |
52-Week High | $490.30 | $123.96 |
52-Week Low | $363.83 | $72.16 |
Enterprise Value | $76.83B | $8.52B |
Dividend Yield | 1.18% | — |
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $406.28, down 1.7% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters and maintains robust profitability with a 17.61% net margin and 99.88% ROE. Recent developments include the $1.5 billion acquisition of D-Fend Solutions and expansion of AI capabilities for emergency response systems, signaling strategic growth in public safety technology.
The outlook remains positive with a consensus price target of $512.33, implying 26% upside, supported by 71% analyst buy ratings. Risks include elevated valuation multiples (P/E 33.1) and significant investing cash outflows for acquisitions. The stock's near-term performance will hinge on execution of growth initiatives and Q2 2026 earnings relative to the $3.86 EPS estimate.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →